Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.

The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.

Service Carveouts; Disease Managemen; Oncology. Vida Healthcare is positioning itselaf as a "value manager" serving patients, physicians and payers as it seeks to develop local best practices in oncology for physicians, intervene with patients and ultimately develop a body of clinical and outcomes information.